2-arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocytes differentiation under inhibitory conditions by Feliú, Ana et al.
R E S E A R CH A R T I C L E
2-arachidonoylglycerol reduces chondroitin sulphate
proteoglycan production by astrocytes and enhances
oligodendrocyte differentiation under inhibitory conditions
Ana Feliu1 | Leyre Mestre1 | Francisco J. Carrillo-Salinas1 | V. Wee Yong2 |
Miriam Mecha1 | Carmen Guaza1
1Functional and Systems Neurobiology
Department, Neuroimmunology Group,
Instituto Cajal, CSIC, Madrid, Spain
2Hotchkiss Brain Institute and the Department
of Clinical Neurosciences and Oncology,
University of Calgary, Calgary, Alberta, Canada
Correspondence
Miriam Mecha Rodríguez and Carmen Guaza,
Instituto Cajal, CSIC, Av. Doctor Arce
37, 28002 Madrid, Spain.
Email: miriammecha@cajal.csic.es (M. M. R.)
and
Email: cgjb@cajal.csic.es (C. G)
Present address
Francisco J. Carrillo-Salinas, Department of
Immunology, Tufts University School of
Medicine, Boston, MA.
Funding information
Ministry of the Economy and Competition,
Grant/Award Numbers: SAF2013-42784-R,
SAF2016-76449-R; Red Española de Esclerosis
Múltiple, Grant/Award Number:
RD16/0015/0021; Ministerio de Economía y
Competitividad, Grant/Award Number: BES-
2014-068459
Abstract
The failure to remyelinate and regenerate is a critical impediment to recovery in mul-
tiple sclerosis (MS), resulting in severe dysfunction and disability. The chondroitin sul-
fate proteoglycans (CSPGs) that accumulate in MS lesions are thought to be linked to
the failure to regenerate, impeding oligodendrocyte precursor cell (OPC) differentia-
tion and neuronal growth. The potential of endocannabinoids to influence MS pro-
gression may reflect their capacity to enhance repair processes. Here, we
investigated how 2-arachidonoylglycerol (2-AG) may affect the production of the
CSPGs neurocan and brevican by astrocytes in culture. In addition, we studied
whether 2-AG promotes oligodendrocyte differentiation under inhibitory conditions
in vitro. Following treatment with 2-AG or by enhancing its endogenous tone
through the use of inhibitors of its hydrolytic enzymes, CSPG production by rat and
human TGF-β1 stimulated astrocytes was reduced. These effects of 2-AG might
reflect its influence on TGF-β1/SMAD pathway, signaling that is involved in CSPG
upregulation. The matrix generated from 2-AG-treated astrocytes is less inhibitory to
oligodendrocyte differentiation and significantly, 2-AG administration directly pro-
motes the differentiation of rat and human oligodendrocytes cultured under inhibi-
tory conditions. Overall, the data obtained favor targeting the endocannabinoid
system to neutralize CSPG accumulation and to enhance oligodendrocyte
differentiation.
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1 | INTRODUCTION
Multiple sclerosis (MS) is a neurodegenerative disease in which
inflammation, demyelination, axonal damage, and gliosis affect the
central nervous system (CNS), leading to progressive neurological
decline and permanent disability (Compston & Coles, 2008; Lassmann,
2017; Lassmann, Bruck, & Lucchinetti, 2001). Repair in MS takes place
spontaneously in the form of remyelination, yet as the disease pro-
gresses remyelination fails (Chang et al., 2012; Chang, Tourtellotte,
Rudick, & Trapp, 2002; Franklin, 2002; Goldschmidt, Antel, Konig,
Bruck, & Kuhlmann, 2009). It appears that this failure of remyelination
is not generally due to a loss of oligodendrocytes at the demyelinated
MS lesions, the CNS cells that produce myelin (Chang et al., 2002,
2012), but rather, to an impediment in the successful remyelination of
damaged axons (Franklin, 2002). Hence, remyelination may be
inhibited by factors in the lesion's extracellular milieu and astrogliosis.
Astrocytes become reactive in MS lesions, facilitating blood–brain
barrier (BBB) repair, secreting immunosuppressive molecules and
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exerting neuroprotective properties. However, astrocytes can also
exacerbate the insult by secreting pro-inflammatory molecules and
they are essential for glial scar formation at demyelinated lesions
(Frischer et al., 2015), sites where there is an increase in the synthesis
and accumulation of chondroitin sulfate proteoglycans (CSPGs) (Back
et al., 2005; Chang et al., 2012; Sobel & Ahmed, 2001).
A basal level of CSPG production is necessary to maintain the
extracellular matrix (ECM) in a state that favors synaptic stabilization
and plasticity (Carulli et al., 2006; Galtrey & Fawcett, 2007). Following
injury, CSPGs are immediately upregulated to limit tissue damage
(Silver & Miller, 2004), yet when CSPG accumulation persists, sponta-
neous repair mechanisms are inhibited due to the formation of a non-
permissive environment that restricts oligodendrocyte precursor cell
(OPC) differentiation (Chang et al., 2012; Karus et al., 2016; Lau et al.,
2012; Pendleton et al., 2013; Siebert & Osterhout, 2011; Sobel &
Ahmed, 2001). Importantly, CSPG clearance through the digestion of
their glycosaminoglycan (GAG) chains, or the blockage of CSPG syn-
thesis and the disruption of CSPG receptors, all provoke remyelination
and axon regeneration in culture, as well as in different experimental
conditions of demyelination and spinal cord injury (SCI) (Bartus et al.,
2014; Dyck et al., 2015; Dyck, Kataria, Akbari-Kelachayeh, Silver, &
Karimi-Abdolrezaee, 2019; Keough et al., 2016; Lang et al., 2015; Lau
et al., 2012; Rolls et al., 2008; Siebert & Osterhout, 2011).
Cannabinoid based therapies are of particular interest in MS, but
also in other pathological scenarios like adenoleukodystrophies, SCI
and a variety of neurodegenerative diseases that require reparative/
remyelination therapeutic approaches. In animal models of MS,
cannabinoids have been found to display the potential to relieve
symptoms and to control inflammation, neurodegeneration, and
demyelination. In general, exogenous and endogenous cannabinoids
can behave as agents with multiple targets acting as an antioxidant
(phytocannabinoids), anti-excitotoxic and neuroprotective lipids
(Fernández-Ruiz, García, Sagredo, Gómez-Ruiz, & de Lago, 2010; Loría
et al., 2010; Mecha et al., 2015; Pryce et al., 2003). Indeed, cannabi-
noid signaling may enhance the activity of reparative mechanisms, as
they can protect OPCs from inflammatory and excitotoxic damage
(Bernal-Chico et al., 2015; Gómez et al., 2010; Mecha et al., 2012;
Molina-Holgado et al., 2002). In particular, the endocannabinoid
2-arachidonoylglycerol (2-AG) promotes the proliferation and differ-
entiation of OPCs (Gómez et al., 2010, 2011, 2015) and it regulates
their migration in culture (Sánchez-Rodríguez, Gómez, Esteban, Gar-
cía-Ovejero, & Molina-Holgado, 2018). Actually, in vivo studies also
demonstrated that inhibiting 2-AG catabolism through the inhibition
of monoacylglycerol lipase (MAGL) or the direct administration of
2-AG attenuates symptomatology and promotes remyelination in the
autoimmune EAE model (Bernal-Chico et al., 2015; Hernández-Torres
et al., 2014; Lourbopoulos et al., 2011), as well as in the Theiler virus
model of MS (Feliu et al., 2017; Mecha et al., 2019). The effects of
2-AG on disease activity and remyelination in the latter progressive
model of MS are dependent on the CB1 and CB2 cannabinoid recep-
tors (CB1R and CB2R), and they involve immune modulation in con-
junction with a reduction in astrogliosis and CSPG deposition (Feliu
et al., 2017).
In the present study, we reveal an effect of 2-AG and the inhibi-
tion of its hydrolytic enzymes on the production of the CSPGs
neurocan and brevican by astrocytes in culture. In addition, we
assessed whether 2-AG promotes oligodendrocyte differentiation
under inhibitory conditions in order to evaluate the potential of the
endocannabinoid system to enhance the endogenous repair mecha-
nisms that are dampened in conditions of chronic demyelination.
2 | MATERIALS AND METHODS
2.1 | Rat astrocyte cell cultures
Rat astrocytes were prepared from postnatal Wistar pups (0–2 days
old) as described previously (Mecha et al., 2011). After isolation, the
astrocytes were plated in Poly-D-lysine (#P7280; 5 μg/ml, Sigma-
Aldrich, Madrid, Spain) coated 6-well plates at a density of 1 × 106
cells/ml for western blot and RT-PCR analysis, or on coverslips in
24-well plates at a density of 3 × 105 cells/ml for immunocytochemis-
try and they were grown at 37C in an atmosphere of 5% CO2 and in
DMEM medium (Lonza Ibérica S.A., Barcelona, Spain) supplemented
with 5% horse serum, 5% fetal bovine serum (FBS; Vector Laborato-
ries Inc, Burlingame, CA), 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Gibco-Invitrogen S.A., Barcelona, Spain). This medium was
replaced 3 hr later, supplemented with cytosine-d-arabinofuranoside
(#C1768, AraC 10 μM: Sigma-Aldrich Madrid, Spain). After 3 days
in vitro, the cells were incubated for 1 hr in serum-free DMEM prior
to the 1, 6, and 24 hr pharmacological treatments. The cells harvested
at 6 hr were processed for RT-PCR, the ones harvested at 24 hr were
processed also for RT-PCR, immunocytochemistry, and CSPGs
were analyzed in western blots, whereas the cells harvested at 1 hr
were used to study signaling pathways. Supernatants from the cells
incubated with the stimuli for 24 hr were analyzed by ELISA.
2.2 | Rat astrocyte-secreted ECM
To generate an anchored astrocyte ECM, astrocytes were seeded on
coverslips in 24-well plates at a density of 3 × 105 cells/ml in DMEM
medium supplemented with 5% horse serum, 5% FBS, 100 U/ml peni-
cillin and 100 mg/ml streptomycin. The medium was replaced 3 hr
later, adding AraC (10 μM). After 3 days in vitro, the cells were incu-
bated for 1 hr in serum-free DMEM prior to treatment for 24 hr with
human TGF-β1 (20 ng/ml: Peprotech, London, UK) and the endo-
cannabinoid 2-AG (100 nM: Tocris Bioscience, Bristol, UK). The cells
were then rinsed with PBS, and treated with Versene (#15040066;
0.2 g/ml EDTA, Gibco-Invitrogen S.A., Barcelona, Spain) for 30 min at
37C and in 5% CO2, and dislodging the cells with a 200 ml micropi-
pette. The cell debris was removed by rinsing with PBS and the
absence of cells was confirmed by phase-contrast microscopy. The
ECM deposited on the 24-well plate was kept hydrated with PBS
(Gibco-Invitrogen S.A., Barcelona, Spain) at 4C until OPCs were
seeded.
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2.3 | Rat oligodendrocyte cultures
Oligodendrocyte cultures derived from P0–P2 Wistar rats were pre-
pared as described previously (Mecha et al., 2011). The cells isolated
were plated on coverslips coated with Poly-D-lysine (5 μg/ml) or a
CSPG mixture (#CC117, 1 μg/ml containing a mixture of aggrecan,
neurocan, phosphacan, and versican: Millipore, Temecula, CA) in
24-well plates at a density of 4 × 105 cells/ml for immunocytochemis-
try. The cells were maintained for 24 hr at 37C and 5% CO2 in Oligo-
dendrocyte medium: serum-free DMEM containing B27, BSA
(0.1 mg/ml: Gibco-Invitrogen, Barcelona, Spain), progesterone (#P6149;
6 ng/ml: Sigma-Aldrich, Madrid, Spain), putrescine (#P7505; 1 μg/ml:
Sigma-Aldrich, Madrid, Spain), sodium selenite (#S9133; 5 ng/ml:
Sigma-Aldrich, Madrid, Spain), T3 (#T5516; 40 ng/ml: Sigma-Aldrich,
Madrid, Spain), Glutamax (#35050061; 2 mM: Gibco-Invitrogen, Barce-
lona, Spain), insulin (#I1882; 5 μg/ml: Sigma-Aldrich, Madrid, Spain),
apotransferrin (#T1147; 25 μg/ml: Sigma-Aldrich, Madrid, Spain), biotin
(#B4639; 2.44 μg/ml: Sigma-Aldrich, Madrid, Spain), hydrocortisone
(#H2270; 10 ng/ml: Sigma-Aldrich, Madrid, Spain), penicillin/strepto-
mycin (#15070063; 1%: Gibco-Invitrogen, Barcelona, Spain), and
sodium pyruvate (#11360070; 1 mM: Gibco-Invitrogen, Barcelona,
Spain). In another set of experiments, isolated oligodendrocytes were
plated for 24 hr in the same media on a rat astrocyte-derived matrix.
2.4 | Human astrocyte cultures
Brain tissue from 18- to 20-week-old therapeutically aborted fetuses
were used in accordance with the ethics approval from the Research
Ethics Board at the University of Calgary. Astrocytes were purified by
dissociating the tissue into single cells, as described previously
(Giuliani, Goodyer, Antel, & Yong, 2003). Briefly, 5–15 g of brain tis-
sue was cut into 1 mm fragments with a pair of scalpels and incubated
for 15 min at 37C in 40 ml PBS containing 0.25% trypsin (Gibco-Invi-
trogen) and 200 g/ml DNase I (Roche Boehringer). The suspension
was then washed through a 130 μm pore size filter, and the flow-
through was centrifuged at 1200 rpm for 10 min. The cell pellet was
resuspended in PBS, centrifuged again and plated in T-75 flasks
coated with 10 μg/ml poly-L-ornithine at a density of 2 × 106 cells/ml
in feeding medium (MEM-supplemented with 10% FBS [Gibco-Invi-
trogen], 0.1% dextrose [Sigma-Aldrich], 1 mM sodium pyruvate
[Gibco-Invitrogen], and 1% penicillin/streptomycin, [Gibco-Invi-
trogen]). The cultures were passaged seven to eight times over
4–5 weeks, depleting the neurons and achieving 95% astrocyte purity.
The flasks were washed with PBS and trypsinized to obtain the astro-
cytes, which were then plated in poly-L-ornithine (10 μg/ml) (Sigma-
Aldrich) coated 6-well plates at a density of 1 × 106 cells/ml, and they
were grown in feeding medium at 37C and in an atmosphere of 5%
CO2. The medium was replaced 3 hr later, adding AraC (10 μM:
Sigma-Aldrich), and after 3 days in vitro, the cells were incubated for
1 hr in serum-free DMEM prior to their pharmacological treatment for
24 hr. The CSPGs in the cells harvested were analyzed in western
blots and the supernatants were used for ELISA studies.
2.5 | Isolation of human oligodendrocytes
Human adult oligodendrocytes were cultured from resected brain
specimens obtained from patients undergoing surgery to treat
intractable epilepsy and they were cultured as described previously
(Nuttall et al., 2007). The tissues used were adjacent to the epileptic
foci in cortical areas and this material was used in accordance with
the ethics approval obtained from the Research Ethics Board at the
University of Calgary. In brief, the pieces of the brain targeted for
excision were suctioned into a sterile bag using a Cavitron Ultrasonic
Aspirator. Tissue fragments less than 2 mm3 were immersed in saline
in the sterile bag at room temperature (23C), which was trans-
ported to the tissue culture laboratory for processing within the
hour of completing the surgery at room temperature. The content of
the sterile bag was put into 50 ml tubes at room temperature, and
the blood, meninges, and clots were removed by washing the tissue
several times with PBS, allowing the contents of the brain to settle
between washes. The tissue was transferred to a sterile 100 ml glass
bottle for digestion with DNase I (0.1 mg/ml, Roche Boehringer) and
0.25% trypsin in PBS, and it was incubated at 37C for 25 min. FBS
was added to inactivate the trypsin and the sample was filtered
through sterile 130 μm mesh. After centrifugation at 1200 rpm for
10 min, the sample was diluted in 21 ml of PBS and laid over 9 ml of
Percoll (GE Healthcare Bio-Sciences AB) in sterile 6–8 polycarbon-
ate ultra-centrifuge tubes. The sample was homogenized using a
pipette and the cells recovered by centrifugation in a Beckman
J2–21 M centrifuge at 15,000 rpm for 30 min at 4C with no brakes.
After Percoll gradient centrifugation, the myelin was removed by
aspiration from the upper layer, and the viable cell layer was pip-
etted and diluted 1:1 in PBS. The cells were washed twice for
10 min by centrifugation at 1200 rpm in MEM containing 0.2 mM
Glutamine, 100 μg/ml penicillin/streptomycin, 1 × nonessential
amino acids, 1 × sodium pyruvate, 0.1% dextrose and 10%
inactivated FBS (all from Gibco-Invitrogen). Finally, the cells were
suspended in medium, plated at 2 x 106 cells/ml in 5 mL uncoated
T25 Flask and incubated for 48 hr at 37C in an atmosphere of 5%
CO2. Microglia strongly adhere to the flask while oligodendrocytes
remained in suspension or were loosely attached. Neurons do not
survive the isolation procedure while astrocytes are lost in the dis-
carded Percoll fractions. The floating oligodendrocytes were col-
lected, centrifuged and plated onto poly-L-ornithine (10 μg/ml) or on
a CSPG mixture (#CC117, 1 μg/ml, Sigma-Aldrich) in 96-well coated
plates at a density of 105 cells/well in human oligodendrocyte
medium: DMEM/F12 (Gibco-Invitrogen) medium containing N2 sup-
plement, Glutamax (2 mM, Gibco-Invitrogen), sodium pyruvate
(1 mM, Gibco-Invitrogen), penicillin/streptomycin (1%, Gibco-Invi-
trogen), insulin (5 μg/ml, Gibco-Invitrogen), holo-transferrin
(50 μg/ml: Sigma-Aldrich), N-acetylcysteine (5 μg/ml: Sigma-Aldrich),
biotin (0.01 μg/ml: Sigma-Aldrich), Trace Elements B, dextrose
(1 mg/ml: Sigma-Aldrich), BSA (0.1 mg/ml: Sigma-Aldrich), proges-
terone (60 ng/ml, Sigma-Aldrich), putrescine (16 μg/ml, Sigma-
Aldrich), Sodium Selenite (30 nM: Gibco-Invitrogen), and T3 (30 nM:
Sigma-Aldrich).
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2.6 | Oligodendrocyte differentiation on a purified
CSPG mixture
To determine the effects of CSPGs on oligodendrocyte growth
in vitro, 96-well plates for human oligodendrocytes and 24-well plates
for rat oligodendrocytes were first coated with 10 μg/ml poly-L-lysine
overnight and then rinsed with water. The plates were coated for
3–4 hr with purified CSPGs (#CC117) at a concentration of 1 μg/ml
diluted in sterile water, then rinsed in water. The control wells con-
tained poly-L-lysine alone. Enriched OPCs were seeded as described
previously and the plates were incubated for 24 hr. The cells were
fixed with 4% ice-cold paraformaldehyde at 4C for 20 min, rinsed
with PBS, and stored at 4C until they were processed for immunocy-
tochemistry. In other experiments, rat OPCs were seeded onto rat
astrocyte secreted ECM.
2.7 | Reagents and treatments
Rat astrocytes were exposed to the cytokine human TGF-β1
(#10021C, 20 ng/ml: Peprotech, London, UK), bFGF (10 ng/ml:
Peprotech, London, UK), the endocannabinoid 2-AG (#1298/10, at
10, 50, 100 nM and 500 nM: Tocris, Bioscience, Bristol, UK), and the
CB1R (SR141716A, 1 μM: Sanofi Recherche, Montpellier, France) and
CB2R (#1120/10, AM630, 1 μM or #5039/10, SR144528 [SR2],
1 μM, both from Tocris Bioscience, Bristol, UK) antagonists for 24 hr,
administered 30 min before 2-AG treatment. In another subset of
experiments, astrocytes were treated for 24 hr with inhibitors of the
2-AG hydrolytic enzymes, the MAGL inhibitors UCM03025 (1 μM:
Department of Organic Chemistry, Universidad Complutense de
Madrid) and JZL184 (#3836/10, 1 μM: Tocris, Bioscience, Bristol, UK),
and an inhibitor of the ABHD6 hydrolase enzyme, WWL70
(#3252/10, 10 μM: Tocris, Bioscience, Bristol, UK). To study cell sig-
naling, TGF-β1, 2-AG, and cannabinoid receptor antagonists were
administered for 1 hr, as well as the inhibitor of the TGFβ-SMAD
pathway, SB431542 (# S4317, 20 μM, Sigma-Aldrich, Madrid, Spain).
Primary human astrocytes were treated for 24 hr with TGF-β1
(10 ng/ml) and 2-AG at 10, 50, and 100 nM. Primary rat oligodendro-
cytes were exposed to 2-AG at concentrations of 100, 500, 1, and
2 μM at time of plating on the CSPG matrix (#CC117, 1 μg/ml), and
the cells were then cultured for 24 hr. Primary human oligodendro-
cytes were exposed to 2-AG at 2 μM at the time of plating on the
CSPG matrix (#CC117, 1 μg/ml) and then cultured for 24 hr.
2.8 | Immunocytochemistry
Treated and fixed astrocytes and oligodendrocytes that had been
maintained in culture for 24 hr were washed in 0.1 M phosphate
buffer (PBS), permeabilized in PBS + 0.2% Triton X-100 (Sigma
Aldrich, Madrid, Spain) (PBT), and then blocked for 1 hr at room tem-
perature in blocking buffer (PBT plus 5% normal goat serum NGS:
Vector Laboratories, Inc., Burlingame, CA). Rat astrocytes were then
stained overnight at 4C with antibodies against neurocan (#1F6 mouse
neurocan diluted 1:1,000, Developmental studies Hybridoma Bank, IA)
and GFAP (#G9269 rabbit GFAP diluted 1:1,000: Sigma-Aldrich,
Madrid, Spain), while rat and human oligodendrocytes were stained
with antibodies against O4 (#MAB345, mouse IgM diluted 1:500:
Millipore, Temecula, CA) and MBP (#MAB382, mouse MBP diluted
1:250: Millipore, Temecula, CA). The following day, the cells were
rinsed and then incubated for 1 hr with the appropriate fluorescent
secondary antibody (Molecular Probes Inc. Eugene, OR): Alexa
594 Fluor-conjugated goat anti-mouse antibody (for neurocan);
Alexa 488 Fluor-conjugated goat anti-rabbit antibody (for GFAP); Alexa
488 Fluor-conjugated goat anti-mouse antibody (for MBP); Texas Red
568 Fluor-conjugated donkey anti-mouse IgM (for O4). Finally, the cells
were counterstained with DAPI (Sigma Aldrich, Madrid, Spain).
2.9 | Western blotting
After treatment, the cultured astrocyte were washed and lysed in
RIPA buffer containing a complete protease inhibitor cocktail
(Roche Diagnostics; Mannheim, Germany). To detect CSPGs, cell
lysates were diluted in chondroitinase ABC buffer (50 mM Tris
[pH 8.0], 60 mM sodium acetate and 0.02% BSA) and then treated
for 3 hr at 37C with 0.1 U/ml chondroitinase ABC from Proteus
vulgaris (#C3667, Sigma-Aldrich, Madrid Spain). To detect the CS-
56 signal, incubation with chondroitinase ABC was omitted. The
reaction was stopped by adding 5 × Laemmli sample buffer and
boiling for 5 min. Equal amounts of protein (15 μg) were resolved
on a 6% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) to
examine CSPGs and on a 10–12% SDS-PAGE for signaling proteins,
and then transferred to a nitrocellulose membrane at 4C
(Amersham Biosciences, Piscataway, NJ). The membranes were
washed with TBS and TBS with 0.1% Tween 20 (TBST), and then
blocked for 1 hr in LI-COR blocking solution. After blocking, the
membranes were washed in TBST and probed overnight with anti-
bodies against: neurocan (#1F6, mouse, Developmental studies
Hybridoma Bank), brevican (#610894, mouse, BD Bioscience, San
Diego, CA), SMAD2 (#MAS-15112, mouse, Thermofisher, MA), p-
SMAD2 (#3108, rabbit, Cell Signaling, MA), SMAD3 (#Ab75512,
mouse, Abcam, Cambridge, UK) and p-SMAD3 (#9520, rabbit, Cell
Signaling, MA), all diluted 1:1,000; and CS-56 diluted 1:500
(#C8035, mouse IgM, Sigma-Aldrich, Madrid, Spain). The mem-
branes were then washed in blocking solution and incubated for
1 hr with the secondary conjugated fluorophores diluted 1:15,000
(IRDye 800CW anti-mouse; IRDye 680LT antimouse IgM; IRDye
680LT anti-rabbit). The membranes were then washed again with
TBST and TBS, and the signal was detected on an Odyssey® CLx
Imaging System (LI-COR Biotechnology, Germany). The signals
were normalized to those obtained for tubulin (#T5168, mouse
diluted 1:10,000, Sigma-Aldrich, Madrid, Spain) or pan-actin
(#D18C11, rabbit diluted 1:1,000, Cell Signaling, MA), and NewBlot
IR Stripping (LI-COR) reagent was used for the stripping procedure
performed for 30 min at room temperature.
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2.10 | ImageXpress acquisition
Images of the 96-well plates of primary human oligodendrocytes
processed for immunocytochemistry were obtained on a Molecular
Device ImageXpress high-content imaging system. The images were
collected at 10 × from six fields per well, with appropriate absorption
and emission wavelengths for each secondary antibody.
2.11 | Image processing and analysis
The images of rat O4 and MBP immunostained oligodendrocytes
were acquired on a Leica TCS SP5 confocal microscope. Briefly, 2 μm
step size confocal stacks were captured in the z-direction from all cells
in 4–5 fields per well and experimental condition, using 20 × objec-
tives, with 2–3 replicates per condition and 3–5 independent experi-
ments were performed. The same threshold was set for all the cells
and all the experimental conditions. Oligodendrocyte morphology was
studied using the Analyze Skeleton plugin of the ImageJ software
(NIH, Bethesda, MD) according to the guidelines of Morrison and
Filosa (2013). Confocal images were acquired and the maximum inten-
sity projection of the O4 or MPB positive channel was used as a noise
filter to eliminate single-pixel background fluorescence, converting
the resulting images to a binary image in order to skeletonize it use
the ImageJ software. All the cells per field and image were analyzed
and averaged to a single data point for each replicate and condition,
collecting the data for the number of branches (total number of ramifi-
cations), joints (bifurcations of ramifications), and end-points (final
points of the ramifications) as a morphological measure of oligoden-
drocyte complexity. The number of cells per field corresponds to the
average of the images per condition.
2.12 | Reverse transcription (RT) and real-
time PCR
Total RNA was extracted from rat astrocyte cultures using RNeasy
mini columns (Qiagen, Manchester, UK), avoiding genomic DNA con-
tamination by DNase I degradation (DNase I, Sigma-Aldrich). The RNA
yield was determined using a Nanodrop spectrophotometer (Thermo
Scientific; Wilmington, DE) and the total RNA (1 μg in 20 μl) was
reverse transcribed into cDNA using poly-dT primers and a reverse
transcription kit (Promega Biotech Ibérica, S.L., Madrid, Spain). Real-
time PCR was carried out with SYBR® using the followed oligonucleo-
tide primer sequences (Applied Biosystems, Warrington, UK): XT-1
forward 50- GGGAATGCAGAAATGGGGGA-30, XT-1 reverse 5´-
GAAGGTCAGAGGTGCGACAA-30; XT-2 forward 5´-GGGTGAGACCC
GCTTCCT-30, XT-2 reverse 5´-CTGAGAGGTAGTTTGCGGTTG-30;
C4ST forward 5´-GGCGCTGCTGGAAGTGAT-30, C4ST reverse
5-AAGATAAAGGATCCGAAGCAA-30; Brevican forward 5´-CCATCC
AGAACCCACGAGA-30 , Brevican reverse 5´-ACCCACCACTCC
GTAATTCC-30; 18S forward 50-ATGCTCTTAGCTGAGTGTCCCG-30 ,
18S reverse 50-ATTCCTAGCTGCGGTATCCAGG-30. After an initial
incubation at 50C for 2 min and 95C for 10 min, PCR amplification
was performed over 40 cycles of 95C for 15 s and 60C for 1 min.
The samples were assayed in triplicate on an Applied Biosystems
PRISM 7500 Sequence detection system. To rule out genomic DNA
contamination, a control sample using RNA that had not been
reversed transcribed was used as the template for each set of extrac-
tions. Gene expression was calculated using the 2−ΔΔCt method and
the relative expression was quantified by calculating the ratio
between the values obtained for each gene of interest and those of
the 18S gene. The results are expressed as a percentage with respect
to the control group.
2.13 | ELISA
The neurocan and brevican levels in supernatants from primary rat
astrocyte cell cultures were measured using specific solid-phase sand-
wich ELISA kits with antibodies against neurocan and brevican respec-
tively, following the manufacturer's recommendations: for neurocan
rat astrocytes - #MBS 450382, My Biosource, San Diego, CA; and for
brevican rat astrocytes #MBS732282, My Biosource, San Diego,
CA. The neurocan levels in human astrocyte cell cultures were mea-
sured by the ELISA kit CSB-EL015513HU Cusabio, Houston, TX, fol-
lowing the manufacturer's recommendations. The minimum
detectable concentration of rat neurocan was 0.055 ng/ml, the detec-
tion range was 0.156–10 ng/ml, and the intra- and inter-coefficient of
variation was 10 and 12%, respectively. The sensitivity of the brevican
assay is 1.0 pg/ml. The detectable limit of human neurocan was
0.078 ng/ml, the detection range was 0.312–20 ng/ml, and the intra-
and inter-coefficient of variation was 8 and 10%, respectively.
2.14 | Statistical analysis
All the data are expressed as the mean ± SEM, using the IBM SPSS
24 statistical software (Inc- IBM, Chicago, IL) for the statistical analy-
sis. One-way ANOVA followed by the Bonferroni and Tukey's post
hoc tests, or a nonparametric Kruskal-Wallis test was employed for
multiple comparisons. The level of significance was set at p ≤ .05.
3 | RESULTS
3.1 | 2-AG treatment diminishes the expression of
enzymes involved in the synthesis of CSPGs and the
levels of neurocan and brevican in rat astrocytes
cultures
CSPGs consist of a core protein with attached sulfate GAG side
chains (Susarla et al., 2011). The synthesis of the GAG chain is car-
ried out by different xylol transferases (XT-1 and XT-2) that consti-
tute the rate-limiting step of GAG synthesis and by the chondroitin
4 sulfotransferase (C4ST). Here first, we show that stimulated
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astrocytes by TGF-β1/bFGF display elevated expression of XT-1
(p < .001 vs. CTL), XT-2 (p < .01 vs. CTL) and C4ST (p < .001 vs. CTL)
transcripts at 6 hr of the incubation period (Figure 1a). The exposure
of 2-AG (100 nM) reduced the mRNA expression of C4ST (p < .05
vs. TGF-β1/bFGF) at 6 hr but at 24 hr the increased expression of
XT-1 (p < .01 vs. CTL) was blunted by the presence of the
endocannabinoid (p < .01 vs. TGF-β1/bFGF). This is reflected in the
reduced gene expression of brevican at the dose of 100 nM 2-AG,
whereas a higher dose of 2-AG (500 nM) was less efficacious as it is
shown in Figure 1a. A dose–response curve of neurocan and
brevican protein production (Figure 1b) reveals that 2-AG 10 nM did
not avoid the release of neurocan and brevican at the extracellular
F IGURE 1 2-AG treatment reduces the expression of enzymes involved in CSPGs synthesis and the levels of neurocan and brevican in
cultured rat astrocytes. (a) RT-PCR analysis of brevican and XT-1, XT2, C4ST enzymes in cell lysates from cultured astrocytes stimulated with
TGF-β1 (20 ng/ml) and bFGF (10 ng/ml) and treated with 2-AG (100 and 500 nM) for 6 and 24 hr. (b) ELISA analysis of extracellular neurocan and
brevican production by rat astrocytes stimulated with TGF-β1 (20 ng/ml) and treated with 2-AG (10, 50, 100, and 500 nM) for 24 hr. The data
represent the mean ± SEM: **p < .01; ***p < .001 versus CTL; #p < .05; ##p < .01; ###p < .001 versus TGF-β1; $ p < .05; $$ p < .01; $$$
p < .001 versus 2-AG treated cells; ns, not significant. One-way ANOVA applied followed by the Bonferroni and Tukey's post hoc tests for ELISAs
analysis and western blot brevican analysis. Nonparametric Kruskal-Wallis test was applied to analyze RT-PCRs (4–5 independent experiments,
3 replicates per experiment). 2-AG, 2-arachidonoylglycerol; CSPGs, chondroitin sulfate proteoglycans
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media of astrocyte cultures. However, although the rest of the doses
were effective in diminishing CSPGs release, the maximal effect of
2-AG for the two CSPGs is achieved by the dose of 100 nM
(p < .001 vs. TGF-β1). These results indicate that the endo-
cannabinoid 2-AG directly interferes with the synthesis of CSPGs in
astrocyte cultures.
3.2 | 2-AG-induced reduction of neurocan is
dependent on the CB2 signaling system in astrocyte
cultures
Astrocytes are the main source of CSPGs (Alonso & Privat, 1993;
Fawcett & Asher, 1999; Reier & Houle, 1988; Silver & Miller, 2004;
F IGURE 2 Legend on next page.
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Susarla et al., 2011), the production of which is stimulated by TGF-β1
in vivo and in vitro (Hamel, Mayer, & Gottschall, 2005; Silver & Miller,
2004; Susarla et al., 2011; Yu, Wang, Katagiri, & Geller, 2012). Immu-
nocytochemical staining for neurocan was weaker in astrocytes
exposed to 2-AG (100 nM) for 24 hr as indicated the quantification of
the neurocan occupied area per cell (Figure 2a). In addition, less
neurocan (Figure 2b), and brevican (Figure 2c) was detected by west-
ern blots following the treatment of 2-AG 100 nM. To assess the
receptors involved in this effect of 2-AG, CB1R (SR141716A, 1 μM)
and CB2R (AM630, 1 μM or SR144528, 1 μM) antagonists were
administered 30 min prior to 2-AG treatment. The reduction of
neurocan production in response to 2-AG was prevented significantly
by prior exposure to the CB2R antagonist (Figure 2b). Furthermore,
exposure of 2-AG alone, without TGF-β1 stimulation did not produce
any increase in CSPGs but rather, there was a reduction in neurocan
relative to the control condition. Similarly, no effect was observed
when cannabinoid receptor antagonists were administered alone. To
further confirm the relevance of CB2R signaling system in neurocan
reduction, we carried out a set of experiments in which we assessed
the levels of neurocan in the extracellular media (Figure 2d) con-
firming that the blockade of CB2R by AM630, but also by SR2
(SR144528) reverted significantly 2-AG-induced reduction of
neurocan (p < .001 vs. TGF-β1 + 2AG 100 nM for AM630 and p < .05
vs. TGF-β1 + 2AG 100 nM for SR2). The ELISA results for brevican
(Figure 2e) confirm the immunoblot data, indicating that CB2 recep-
tors are not involved in 2-AG-induced reduction of brevican.
3.3 | The increase in 2-AG tone by inhibiting
hydrolyzing enzymes dampens neurocan and brevican
expression, diminishing the extracellular levels of both
CSPGs
We further assessed how 2-AG affects CSPG production by increas-
ing its tone through exposure to inhibitors of 2-AG hydrolysis by the
MAGL and ABHD6 enzymes. As such, TGF-β1 stimulated astrocytes
were treated for 24 hr with two MAGL inhibitors (the reversible inhib-
itor UCM03025, 1 μM, and an irreversible inhibitor JZL184, 1 μM),
and one inhibitor of the ABHD6 enzyme (WWL70, 10 μM). The gen-
eration of neurocan (Figure 3a) and brevican (Figure 3b) was reduced
significantly by inhibitors of 2-AG hydrolysis when measured by west-
ern blots. ELISA results confirm immunoblot data. Thus, extracellular
neurocan (Figure 3c) was also significantly diminished in astrocytes
exposed to MAGL inhibitors (p < .001 vs. TGF-β1) and to the ABHD6
inhibitor WWL70 (p < .05 vs. TGF-β1) although in that case in less
degree than in the case of the MAGL inhibitor JLZ (p < .05 vs. TGF-
β1 + JLZ). Extracellular brevican levels (Figure 3d) were also signifi-
cantly diminished by all the 2-AG hydrolysis enzymes (p < .001
vs. TGF-β1).
3.4 | 2-AG treatment reduces the phosphorylation
of SMAD2 in TGF-β1 treated astrocytes, an effect
possibly mediated through CB2 receptor signaling
The TGF-β1-SMAD pathway is a canonical signaling pathway involved
in CSPG synthesis by cultured astrocytes (Schachtrup et al., 2010;
Susarla et al., 2011). To assess how 2-AG provokes a reduction in
CSPGs, we examined the phosphorylation of SMAD2 and SMAD3 in
TGF-β1 stimulated astrocytes treated with 2-AG (100 nM) for 1 hr,
assessing the potential involvement of the CB1R and CB2R through
the addition of specific antagonists (SR141716A, 1 μM and AM630,
1 μM) 30 min prior to 2-AG treatment. Our results confirmed that the
TGF-β1–SMAD signaling pathway is activated in the stimulated astro-
cytes as the phosphorylation of both SMAD2 and SMAD3 proteins
was enhanced in these conditions (Figure 4a,b). SMAD2 phosphoryla-
tion was significantly dampened by 2-AG treatment, yet it reverted to
TGF-β1 levels in cells also exposed to the CB2R antagonist
(Figure 4a). No significant effect was observed in the case of SMAD3
phosphorylation (Figure 4b).
3.5 | 2-AG treatment reduces CSPG expression
and extracellular neurocan levels in human astrocytes
in culture
Human astrocytes are known to synthesize CSPGs in culture when
stimulated (Keough et al., 2016), so we examined the CSPGs produced
by primary human astrocytes isolated from therapeutically aborted
human fetuses that were treated for 24 hr with TGF-β1 (10 ng/ml)
and 2-AG at concentrations of 10, 50, and 100 nM. In western blots
probed with the CS-56 antibody, the expression of CSPGs was
induced in TGF-β1 stimulated astrocytes, although this effect was sig-
nificantly weakened by the administration of 2-AG at 50 and 100 nM
F IGURE 2 2-AG treatment reduces the expression of CSPGs in cultured rat astrocytes and the reduction in neurocan is dependent on the
CB2 receptor signaling. Cultured astrocytes were stimulated with TGF-β1 (20 ng/ml) and treated with 2-AG (100 nM) for 24 hr.
(a) Representative immunocytochemistry of neurocan (red) and GFAP (green) in primary astrocytes together with the quantification of neurocan
expression. Western blots of cell lysates probed for (b) neurocan and (c) brevican. ELISA analysis of extracellular neurocan (d), and brevican
(e) production by rat astrocytes stimulated with TGF-β1 (20 ng/ml) and treated with 2-AG (100 nM), and CB2R antagonists for 24 hr. CB1R
(SR141716A, 1 μM) and CB2R (AM630, 1 μM and SR144528, 1 μM) antagonists were added 30 min before 2-AG. Scale bar: 50 and 100 μm. The
data represent the mean ± SEM: **p < .01; ***p < .001 versus CTL; #p < .05; ###p < .001 versus TGF-β1; $ p < .05; $$ p < .01; $$$ p < .001
versus TGF-β1 + 2-AG; ns, not significant. One-way ANOVA applied followed by the Bonferroni and Tukey's post hoc tests for ELISAs analysis
and western blot brevican analysis. A nonparametric Kruskal–Wallis test was applied to analyze neurocan by western-blot (5–6 independent
experiments, 3 replicates per experiment). 2-AG, 2-arachidonoylglycerol; CSPGs, chondroitin sulfate proteoglycans
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(Figure 5a). In addition, there was less extracellular neurocan evalu-
ated by ELISA measurement when astrocytes were exposed to 2-AG
(Figure 5b), in that case, extracellular levels of neurocan were
diminished by 2AG 10 nM and the levels of neurocan were negligible
by the doses of 2-AG 50 and 100 nM. These results suggest that
human astrocytes may be most sensitive to the actions of 2-AG.
F IGURE 3 Inhibitors of 2-AG hydrolysis reduce neurocan and brevican expression and its extracellular levels by cultured rat astrocytes. Rat
astrocytes were stimulated with TGF-β1 (20 ng/ml) and treated for 24 hr with two MAGL inhibitors (the reversible, UCM03025 [1 μM] or the
irreversible, JZL 184 [1 μM]) or an inhibitor of the ABHD6 enzyme (WWL70 [10 μM]). Both neurocan and brevican expression and its
extracellular levels were analyzed by western blots (a and b, respectively) and ELISA assays (c and d, respectively). The data represent the mean
± SEM: *p < .05; **p < .01; ***p < .001 versus CTL; #p < .05; ##p < .01; ###p < .001 versus TGF-β1; $ p < .05 vs TGF-β1 + JZL. Nonparametric
Kruskal-Wallis test for western-blot analysis and one-way ANOVA applied followed by the Bonferroni and Tukey's post hoc tests for ELISAs
analysis (4–5 independent experiments with 3 replicates per experiment)
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F IGURE 4 2-AG dampens SMAD2 phosphorylation in TGF-β1 treated astrocytes, an effect possibly mediated through CB2 signaling.
Astrocytes were stimulated with TGF-β1 (20 ng/ml) and treated with 2-AG (100 nM) for 1 hr. The phosphorylation of SMAD2 and SMAD3
proteins were analyzed by western blots. CB1R (SR141716A 1 μM) and CB2R (AM630 1 μM) antagonists were added 30 min before 2-AG
administration, and SB431542 (20 μM) was used to inhibit SMAD signaling. The data represent the mean ± SEM: ***p < .001 versus CTL;
#p < .05 versus TGF-β1; ###p < .001; $$ p < .01 versus TGF-β1 + 2-AG. ns, not significant. Nonparametric Kruskal-Wallis test (four independent
experiments, three replicates per experiment). 2-AG, 2-arachidonoylglycerol [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 5 Treatment with 2-AG reduces CSPG expression and neurocan extracellular levels by cultured human astrocytes. (a) Expression of
CSPGs by human fetal astrocytes evaluated by probing western blots with the CS-56 antibody and (b) neurocan secretion evaluated by ELISA in
human fetal astrocytes stimulated with TGF-β1 (10 ng/ml) and treated for 24 hr with 2-AG at a concentration of 10, 50, and 100 nM. The data
represent the mean ± SEM: *p < .05; **p < .01versus CTL; #p < .05, ##p < .01; ###p < .001 versus TGF-β1. ns, not significant. ND, not
detectable. One-way ANOVA test followed by the Bonferroni and Tukey's post hoc tests (four independent experiments, three replicates per
experiment). 2-AG, 2-arachidonoylglycerol; CSPGs, chondroitin sulfate proteoglycans
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3.6 | The matrix generated by astrocytes exposed
to 2-AG is less inhibitory to oligodendrocyte
differentiation
We next tested the effect of restricting rat astrocyte CSPG synthesis
on rat OPC differentiation in culture. As such, we seeded astrocytes
in 24-well plates and treated them with TGF-β1 (20 ng/ml) and 2-AG
(100 nM) for 24 hr to alter the proportion of CSPGs in the ECM
secreted and deposited on the base of the plate. After treatment and
in order to avoid any effect produced by cell–cell contact between
astrocytes and OPCs, astrocytes were removed from the plate using
Versene (0.2 g/ml EDTA). Rat OPCs were then plated on the ECM
F IGURE 6 The 2-AG treated astrocyte matrix is less inhibitory for oligodendrocyte differentiation. Rat oligodendrocytes cultured for 24 hr on
a matrix generated by rat astrocytes stimulated with TGF-β1 (20 ng/ml) and treated with 2-AG (100 nM) for 24 hr. (a) Representative
immunocytochemistry for O4 (yellow) and DAPI (blue), and their respective skeletons. (b) The number of O4 positive cells/field. (c) Branches,
junctions, and end-points obtained from the skeleton data. Scale bar: 50 μm. The data represent the mean ± SEM: **p < .01 versus CTL; #p < .05
versus TGF-β1. ns, not significant. One-way ANOVA test followed by the Bonferroni and Tukey's post hoc tests (three independent experiments,
three replicates per experiment). 2-AG, 2-arachidonoylglycerol
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generated and the outgrowth of processes was analyzed after 24 hr
by immunocytochemistry for O4 staining (Figure 6a), while the mor-
phological complexity of the OPCs was assessed by measuring their
branches, junctions and end-points (Figure 6c). We found that OPCs
plated onto a TGF-β1 stimulated astrocyte matrix developed a less
complex morphology than those plated onto a control matrix,
suggesting a weaker differentiation. The matrix produced by 2-AG
treated astrocytes induced more outgrowth of OPC processes, with
more branches, junctions and end-points. No effect was observed on
the initial cell adhesion under any experimental condition
(Figure 6b).
3.7 | 2-AG treatment promotes oligodendrocyte
differentiation under inhibitory conditions
To study whether 2-AG directly promotes the differentiation of OPCs
plated onto an inhibitory ECM, rat OPCs were enriched from mixed
glial cultures and they were seeded onto 24-well plates coated with a
commercial mixture of CSPGs (#CC117; 1 μg/ml, mostly containing
neurocan, phosphacan, versican, and aggrecan). These cells were then
exposed to 2-AG for 24 hr at concentrations of 100, 500,1, and 2 μM,
and their morphological complexity was analyzed after staining for O4
(Figure 7a) and MBP (Figure 8a). Cell adhesion to the mixture of
F IGURE 7 2-AG promotes the differentiation of O4 positive oligodendrocytes cultured on an inhibitory substrate. Rat oligodendrocytes
cultured for 24 hr on a synthetic CSPG matrix (#CC117, 1 μg/ml) and treated for 24 hr with 2-AG at 100, 500, 1, and 2 μM. (a) Representative
immunocytochemistry for O4 (yellow) and DAPI (blue), and their skeletons. (b) The number of O4 positive cells/field (c) Branches, junctions, and
end-points obtained from the skeleton data. Scale bar: 50 μm. The data represent the mean ± SEM: ***p < .001 versus CTL; #p < .05 versus
CC117. ns, not significant. Nonparametric Kruskal-Wallis test (five independent experiments, two replicates per experiment). 2-AG,
2-arachidonoylglycerol; CSPGs, chondroitin sulfate proteoglycans
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CSPGs was worse (Figures 7b and 8b) and this matrix significantly
inhibited the outgrowth of oligodendrocytes, producing fewer arbori-
zations (Figures 7a and 8a) and less complexity in terms of branches,
junctions, and end-points (Figures 7c and 8c). By contrast, OPCs that
were plated onto CSPGs and immediately exposed to 2-AG developed
elaborated arborizations that reached a significant level in the case of
2-AG 1 and 2 μM for O4 staining (Figure 7c; p < .05 vs. CC117). The
staining with MBP also was affected by the treatment with 2-AG as
we observed an increase in the morphological complexity of the cells
that reached statistical significance with at 2 μM dose (Figure 8c;
p < .05 vs CC117). The endocannabinoid treatment did not modify
the number of O4 positive cells adhere the inhibitory substrate
(Figure 7b) but a significant increase in the number of MBP positive
cells at doses of 1 and 2 μM were observed (Figure 8b; p < .01 and
p < .001 vs. CC117, respectively).
To study the effects of 2-AG on human oligodendrocyte out-
growth, we isolated primary human OPCs from surgically resected
brain tissue obtained from patients with refractory epilepsy to treat-
ments. These cells were seeded onto 24-well plates coated with the
commercial CSPG mixture (1 μg/ml) and they were immediately
treated for 24 hr with 2-AG (2 μM), staining the cells for O4 (Figure 9)
to analyze their morphology using ImageJ. The adhesion of these cells
to the commercial CSPG matrix was not significantly impaired, as eval-
uated by the number of O4 positive cells attached to the plate
(Figure 9b). However, there was a significantly poorer outgrowth of
processes, with fewer arborizations evident through O4
F IGURE 8 2-AG promotes the differentiation of MBP positive oligodendrocytes on an inhibitory substrate. Rat oligodendrocytes cultured for
24 hr on a synthetic CSPGs matrix (#CC117, 1 μg/ml) and treated for 24 hr with 2-AG at 100, 500, 1, and 2 μM. (a) Representative
immunocytochemistry for MBP (green) and DAPI (blue), and their skeletons. (b) The number of MBP positive cells/field (c) Branches, junctions,
and end-points obtained from the skeleton data. Scale bar: 100 μm. The data represent the mean ± SEM: ***p < .001 versus CTL; # p < .05, ##
p < .01, ### p < .001 versus CC117. ns, not significant. One-way ANOVA test followed by the Bonferroni and Tukey's post hoc tests were used
for complexity analysis and non-parametric Kruskal-Wallis test for the number of cells analysis (three independent experiments, two replicates
per experiment). 2-AG, 2-arachidonoylglycerol; CSPGs, chondroitin sulfate proteoglycans
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immunocytochemistry (Figure 9a) and a reduced complexity when
branches, junctions and end-points were analyzed (Figure 9c; p < .001
vs. CTL). By contrast, human OPCs plated on CSPGs and treated with
2-AG (2 μM) displayed significantly more elaborated arborizations
(Figure 9c; p < .01 vs. CC117), but again, there was no effect on their
adhesion (Figure 9b).
4 | DISCUSSION
In recent years, the interest in astrocytes as potential targets for neu-
rotherapies has grown, particularly given their role as primary media-
tors of reactive gliosis and in maintaining immune homeostasis in the
brain, along with microglia. Currently, therapies targeting the
F IGURE 9 2-AG promotes the differentiation of human oligodendrocytes cultured on an inhibitory substrate. Human oligodendrocytes
obtained from biopsies and cultured for 24 hr on a synthetic CSPGs matrix (#CC117, 1 μg/ml) and treated with 2-AG (2 μM). (a) Representative
immunocytochemistry for O4 (green) and DAPI (blue), and their respective skeletons. (b) The number of O4 positive cells/field (c) Branches,
junctions, and end-points obtained from the skeleton data. The data represent the mean ± SEM: ***p < .001 versus CTL; ##p < .01 versus CC117.
ns, not significant. One-way ANOVA test followed by the Bonferroni and Tukey's post hoc tests (representative experiment, five replicates per
condition). 2-AG, 2-arachidonoylglycerol; CSPGs, chondroitin sulfate proteoglycans
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inflammatory component of MS have helped reduce the frequency of
relapses, yet they are ineffective in halting disease progression. Clini-
cal and experimental data suggest that such therapies do not enhance
endogenous remyelination and regeneration sufficiently in the pro-
gressive phase of MS. Then, it is important to develop therapies that
enhance reparative processes. CSPGs are molecules that may inter-
fere with endogenous repair mechanisms, particularly as they accumu-
late in the glial scar. They are considered inhibitory molecules that
impede remyelination and regeneration. In order to promote repara-
tive mechanisms, combined therapies that neutralize the inhibitory
environment around the demyelinated lesions and that enhance oligo-
dendrocyte differentiation would favor the remyelination processes.
In this study, we addressed whether the endocannabinoid 2-AG
reduces the production of CSPGs by astrocytes in culture and
whether the ECM generated by 2-AG-treated astrocytes is less inhibi-
tory to oligodendrocyte differentiation. In addition, the effect of 2-AG
on oligodendrocyte differentiation was assessed in the presence of a
synthetic ECM enriched in CSPGs.
By secreting cytokines and chemokines that alter immune
responses, astrocytes can potentiate inflammatory responses in situa-
tions of infection, trauma, ischemia, or neurodegenerative pathologies.
Indeed, they are the main mediators of reactive gliosis, and they are
responsible for CSPG synthesis and glial scar formation, a pathological
feature of MS (Sofroniew & Vinters, 2010; Wu & Raine, 1992). The
increase we found in neurocan and brevican by TGF-β1-stimulated
astrocytes is similar to that seen previously (Asher et al., 2000; Gris,
Tighe, Levin, Sharma, & Brown, 2007; Hamel et al., 2005; Jones, Mar-
golis, & Tuszynski, 2003; McKeon, Jurynec, & Buck, 1999; Schachtrup
et al., 2010; Sobel, 2001; Tang, Davies, & Davies, 2003; Wang et al.,
2008), evidence that this cytokine enhances the expression of a whole
battery of enzymes responsible for CSPG production by astrocytes
(Asher et al., 2000; Gris et al., 2007; Hamel et al., 2005; Smith &
Strunz, 2005; Wang et al., 2008) in agreement with the results of the
present study. In addition, the enhanced neurocan by immunostaining
and ELISAs have also been observed previously (Asher et al., 2000;
Smith & Strunz, 2005). Notably, TGF-β1 induces a similar response in
rat and human astrocytes, increasing CSPG production as evident in
western blots and ELISAs, an effect seen previously by other groups
(Keough et al., 2016).
TGF-β1-SMAD signaling is the canonical pathway involved in
CSPGs production (Massague, Seoane, & Wotton, 2005) and SMAD2
and SMAD3 knockdown reduce CSPG production by astrocytes
(Susarla et al., 2011). Activation of this pathway was also evident here
and following TGF-β1 stimulation of astrocytes, there is an increment
in SMAD2 and SMAD3 phosphorylation likely associated with
enhanced neurocan and brevican synthesis.
Regarding the endocannabinoid system, we convincingly show
that 2-AG diminished the production of CSPGs by rat and human
astrocytes. We provide evidence that 2-AG reduces the expression of
the enzymes involved in the synthesis of CSPGs, XT-1, and CS4T, and
that 2-AG is capable to reduce the gene expression of brevican. Con-
sequently, the effect of 2-AG seems to be independent of the activity
of matrix metalloproteinases (MMPs) that would degrade CSPGs.
Although these enzymes could be acting at extracellular level
degrading secreted CSPGs from astrocytes and we cannot discard
completely the influence of MMPs activity on the effects of 2-AG at
extracellular level, there is evidence showing that endocannabinoids
inhibit hypoxia-induced MMP9 and MMP2 activities
(Mukhopadhyay & Tulis, 2007).
Interestingly, direct exposure of stimulated astrocytes to 2-AG
dampens SMAD2 phosphorylation, in conjunction with reduced intra-
cellular and extracellular levels of neurocan and brevican. In addition,
we also observed a reduction in CSPG expression and extracellular
release when TGF-β1 stimulated human astrocytes were treated with
2-AG. The increase of 2-AG by the inhibition of MAGL and ABHD6
also reduces the intracellular expression of brevican and neurocan.
The reduction in CSPG expression by MAGL inhibitors and by 2-AG in
cultured astrocytes is consistent with our previous data obtained
in vivo, whereby administration of the same MAGL inhibitor
(UCM03025) reduced astrogliosis and CSPG accumulation in the spi-
nal cord of a chronic progressive mouse model of MS (Feliu et al.,
2017). Indeed, 2-AG and other MAGL inhibitors were previously
shown to attenuate symptoms in the EAE model (Bernal-Chico et al.,
2015; Hernández-Torres et al., 2014; Lourbopoulos et al., 2011). It is
important to remark that in the present study MAGL is the hydrolysis
enzyme that plays the main role in regulating the availability of 2-AG
to reduce neurocan (in agreement with MAGL high expression in
astrocytes), whereas ABDH6 may play a secondary role that in con-
junction with MAGL is also crucial for the reduction of neurocan.
Although inhibitors of the ABHD6 enzyme produced a similar reduc-
tion in intracellular and extracellular brevican despite hydrolyzing only
3% of the 2-AG, the therapeutic effect of ABHD6 inhibitors in vivo
remains controversial. While there is evidence that inhibiting ABDH6
produces therapeutic effects in a CNS injury model (Tchantchou &
Zhang, 2013) or in the EAE model of MS (Wen, Ribeiro, Tanaka, &
Zhang, 2015), only modest effects were observed when ABHD6 was
inhibited by KT182 in the cuprizone model of demyelination and in
EAE (Manterola et al., 2018; Manterola et al., 2018). Our observations
strongly suggest that 2-AG dampens the production of neurocan and
brevican in TGF-β1 stimulated astrocytes by modulating SMAD
signaling.
2-AG is a full agonist of the CB1 and CB2 cannabinoid receptors
(Sugiura, Kishimoto, Oka, & Gokoh, 2006). Nevertheless, in our study
only CB2R antagonism significantly blocked the effects of 2-AG on
the phosphorylation of SMAD2 and on neurocan expression,
suggesting that the reduction in neurocan induced by 2-AG is medi-
ated through CB2R signaling. Although CB2R expression in astrocytes
remains controversial, this receptor may be upregulated in astrocytes
under inflammatory conditions. Indeed, CB2R expression has been
described in GFAP+ cells bordering white matter lesions in postmor-
tem samples from MS patients (Benito et al., 2007), as well as in astro-
cytes in a model of SCI (García-Ovejero et al., 2009). In addition,
CB2R activation modulates the production of different immune medi-
ators in LPS-stimulated astrocytes treated with a selective endo-
cannabinoid uptake inhibitor (Ortega-Gutiérrez, Molina-Holgado, &
Guaza, 2005), an effect that is also observed when human astrocytes
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are exposed to the synthetic cannabinoid WIN55,212-2 (Sheng et al.,
2005). Indeed, CB2R activation in astrocytes, together with the acti-
vation of the CB1R in neurons, is responsible for the beneficial actions
of the potent synthetic cannabinoid, HU210, in a progressive model
of MS (Docagne et al., 2007).
Several studies have focused on the modulation of the endo-
cannabinoid system in order to regulate fibrotic responses in experi-
mental models where there is an accumulation of collagen and ECM
proteins. The CB1R has been identified as a pro-fibrotic receptor
(Marquart et al., 2010; Yoshinaga et al., 2016), as corroborated in FAAH
deficient mice in which the induction of fibrosis is dependent on the
CB1R (Palumbo-Zerr et al., 2012). However, we did not find the CB1R
to be involved in the 2-AG-induced reduction of CSPG production by
astrocytes. By contrast, our data highlights the involvement of the
CB2R in the reduction of neurocan induced by 2-AG. The dampening
of fibrotic processes by the CB2R has also been described in experi-
mental models of skin fibrosis and tissue damage (Akhmetshina et al.,
2009). More recent studies showed that an antagonist of the CB2R
augments collagen synthesis in association with TGF-β1 signaling and
SMAD phosphorylation (Li et al., 2016). In addition, agonists of PPARγ
and CB2Rs (julemic acid or the compound VCE-004.8, respectively),
promote anti-fibrotic responses in experimental models of systemic
sclerosis (Del Río et al., 2016; González et al., 2012). Moreover, activa-
tion of CB2Rs provokes anti-fibrotic responses through the inhibition
of the TGF-β1/SMAD pathway in a Nrf2 dependent manner (Li et al.,
2016). All these studies are consistent with the results obtained here
on the effects of 2-AG in reducing SMAD phosphorylation and
neurocan production through CB2R signaling.
The ECM generated by astrocytes in culture and a commercial
ECM enriched in CSPGs both inhibit neurite outgrowth and oligoden-
drocyte differentiation (Cua et al., 2013; Karus et al., 2016; Keough
et al., 2016; Lau et al., 2012; Pendleton et al., 2013; Siebert &
Osterhout, 2011). Accordingly, both ECMs reduce OPC maturation,
although our astrocyte ECM inhibited oligodendrocyte differentiation
less strongly than the commercial ECM, in contrast to an earlier study
(Keough et al., 2016). The relative amounts of CSPGs probably differ
between astrocyte and commercial ECMs, and moreover, the
astrocyte-ECM is likely to have undefined factors that could help res-
cue the inhibitory effect of the CSPGs secreted by astrocytes. Indeed,
such factors may explain some effects observed when oligodendro-
cytes are cultured on astrocyte-generated ECM. We also found that
commercial CSPG-enriched ECM not only reduced human oligoden-
drocyte adhesion to the matrix but also their morphological complex-
ity. Importantly, a significant reduction in the outgrowth of processes
was also observed when human oligodendrocytes were cultured on
this inhibitory ECM, although there was no reduction in the number
of cells adhered to the matrix (Lau et al., 2012). Such, differences per-
haps may be due to the distinct concentrations of commercial CSPGs
used in the two studies (50 vs. 1 μg/mL in our study).
2-AG can promote oligodendrocyte differentiation indirectly
through the generation of a less inhibitory ECM that modulates astro-
cyte responses, or by directly acting on oligodendrocytes to enhance
their differentiation. Here, treating cultured astrocytes with 2-AG
reduces the inhibitory ECM generated by astrocytes, enhancing oligo-
dendrocyte outgrowth. Our results are consistent with astrocyte cul-
tures producing an ECM rich in CSPGs that are inhibitory to neurite
outgrowth, this inhibition being partly overcome by chondroitinase
ABC digestion and that of other agents (Cua et al., 2013). Interest-
ingly, the ECM generated by astrocytes treated with Fluorosamine, a
compound that dampens CSPG secretion, can also elevate oligoden-
drocyte outgrowth in culture (Keough et al., 2016). Encouragingly,
2-AG also enhances oligodendrocyte outgrowth even when cultured
on the CSPG enriched commercial ECM, a beneficial effect that
occurs when human oligodendrocytes are cultured under the same
condition. The effects of 2-AG on the production of growth factors
that could contribute to the generation of a more permissive environ-
ment for oligodendrocyte maturation in conjunction with reduced
CSPG expression still needs to be clarified.
The promotion of oligodendrocyte maturation by 2-AG was
reproduced by administering this endocannabinoid or by impeding its
hydrolysis by inhibiting MAGL, inducing OPC proliferation and differ-
entiation in vitro (Bernal-Chico et al., 2015; Gómez et al., 2010, 2011,
2015), and regulating their migration in culture (Sánchez-Rodríguez
et al., 2018). These effects are mediated through CB1R and CB2R
both present on OPCs and mature oligodendrocytes, being the Pi3k-
Akt signaling pathway involved in the promotion of oligodendrocytes
differentiation by the endocannabinoid (Gómez et al., 2010, 2011). As
such, following exposure to 2-AG or an increase in its endogenous
tone, there is enhanced oligodendrocyte proliferation and differentia-
tion that leads to successful remyelination in different models of
demyelination in vivo: the TMEV-IDD model (Feliu et al., 2017), the
EAE model of MS (Lourbopoulos et al., 2011) and the cuprizone model
(Bernal-Chico et al., 2015). It is particularly interesting that both 2-AG
and one inhibitor of the MAGL enzyme both reduce excitotoxic oligo-
dendrocyte death (Bernal-Chico et al., 2015), an effect also attributed
to other cannabinoids and under another toxic stimulus (Mecha et al.,
2012; Ribeiro, Yu, Wen, Vana, & Zhang, 2013).
Understanding the mechanisms that prevent remyelination in MS
is critical to developing effective therapies that promote repair and
remyelination in the progressive phase of MS. Astrocytes could be an
interesting therapeutic target to bear in mind to reduce CSPG produc-
tion and accumulation in demyelinated areas, also enhancing pro-
regenerative responses. However, there is evidence that astrogliosis is
not uniformly inhibitory to repair, then, our knowledge of the role of
glial scar in tissue remodeling required intense research to untangle
the complex interactions between neurons, axons, and glial cells.
Actually, 2-AG could act as a multi-target agent, not only as an
immunomodulatory and neuroprotective lipid but also, targeting
astrocytes to reduce their CSPG accumulation with beneficial effects
on oligodendrocytes differentiation. The findings reported here sug-
gest promising avenues of research and potential treatments for
demyelinating pathologies.
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